Celgene Stock Price, News & Analysis (NASDAQ:CELG)

$102.91 0.26 (0.25 %)
(As of 01/23/2018 08:49 AM ET)
Previous Close$102.65
Today's Range$99.99 - $103.50
52-Week Range$94.55 - $147.17
Volume12.93 million shs
Average Volume8.45 million shs
Market Capitalization$81.02 billion
P/E Ratio24.27
Dividend YieldN/A
Beta1.77

About Celgene (NASDAQ:CELG)

Celgene logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CELG
CUSIP15102010
Phone+1-908-6739000

Debt

Debt-to-Equity Ratio1.31%
Current Ratio3.65%
Quick Ratio3.52%

Price-To-Earnings

Trailing P/E Ratio24.2712264150943
Forward P/E Ratio15.34
P/E Growth0.65

Sales & Book Value

Annual Sales$11.23 billion
Price / Sales7.22
Cash Flow$6.04 per share
Price / Cash17.05
Book Value$8.51 per share
Price / Book12.09

Profitability

Trailing EPS$4.24
Net Income$2.00 billion
Net Margins27.36%
Return on Equity63.80%
Return on Assets17.45%

Miscellaneous

Employees7,132
Outstanding Shares787,320,000

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) announced its earnings results on Thursday, October, 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.04. The biopharmaceutical company earned $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene's revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.58 EPS. View Celgene's Earnings History.

When will Celgene make its next earnings announcement?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, January, 25th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene updated its FY18 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of $8.70-8.90 for the period, compared to the Thomson Reuters consensus estimate of $8.70. The company issued revenue guidance of $14.4-14.8 billion, compared to the consensus revenue estimate of $14.84 billion.Celgene also updated its Q4 guidance to $2.00 EPS.

Where is Celgene's stock going? Where will Celgene's stock price be in 2018?

30 brokerages have issued 12-month price objectives for Celgene's stock. Their predictions range from $91.00 to $166.00. On average, they expect Celgene's stock price to reach $130.14 in the next twelve months. View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:

  • 1. Cantor Fitzgerald analysts commented, "The Wall Street Journal (WSJ) has reported that CELG is in talks to buy JUNO (NC), or rather the 90% of the company that CELG does not already own." (1/17/2018)
  • 2. According to Zacks Investment Research, "Celgene’s Revlimid continue to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Pomalyst and Abraxane also performed well. The approval of Idhifa for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. However, Celgene is highly dependent on Revlimid. Celgene suffered a setback as the label expansion study on lead drug Revlimid failed in phase III. The drug’s label expansion would have boosted its sales potential. Additionally, the deep yet persistently slow growth of the psoriatic arthritis and psoriasis markets, especially during the entire third quarter, has led to a weak performance of Otezla. Consequently, the company also reduced its annual guidance. Shares have underperformed the industry in the last six months. " (1/8/2018)
  • 3. Cann analysts commented, "We conducted a physician survey to evaluate the current treatment preferences and satisfaction with available therapies, along with expectations for therapies in clinical development. Our report (published 11/21/17), Multiple Sclerosis Survey: Unmet Need Persists Despite Several Approved Treatment Options, concluded that there is a meaningful unmet need in MS treatment and a high level of interest in Ozanimod if FDA-approved. We conclude that approximately 80% of the neurologists surveyed are unsatisfied with the therapies available to them. The survey showed that 40.4% of patients are being treated with oral therapy. The surveyed neurologists replied that they would, on average, put 23.8% of their patients on a newly approved therapy they had selected from the survey." (11/22/2017)
  • 4. BTIG Research analysts commented, "After mkt-close on Thursday, Celgene announced termination of the Phase 3 studies (REVOLVE and SUSTAIN) for mongersen in the treatment of Crohn’s disease, and that the Phase 3 DEFINE study will not be initiated. Termination of the programs follow the recommendation of the Data Monitoring Committee (DMC) who indicated futility of mongersen in producing a clinical benefit. Based on the announcement, we have taken our 2023 mongersen estimates to zero from $215m previously, versus consensus at ~$1bn." (10/22/2017)

Are investors shorting Celgene?

Celgene saw a increase in short interest in December. As of December 15th, there was short interest totalling 13,477,756 shares, an increase of 17.1% from the November 30th total of 11,514,288 shares. Based on an average daily trading volume, of 5,987,801 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.7% of the company's shares are short sold.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board (Age 62)
  • Scott A. Smith, President, Chief Operating Officer (Age 55)
  • Mark J. Alles, Chief Executive Officer, Director (Age 58)
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President (Age 61)
  • Terrie Curran, President, Global Inflammation & Immunology Franchise (Age 48)
  • Michael F. Pehl, President, Hematology & Oncology (Age 52)
  • Rupert J Vessey, President - Research and Early Development (Age 52)
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary (Age 49)
  • Michael D. Casey, Lead Independent Director (Age 71)
  • Michael W. Bonney, Director (Age 59)

Who owns Celgene stock?

Celgene's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.41%), Bank of Montreal Can (0.39%), Chevy Chase Trust Holdings Inc. (0.09%), Factory Mutual Insurance Co. (0.09%), National Pension Service (0.08%) and DAVENPORT & Co LLC (0.08%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Who sold Celgene stock? Who is selling Celgene stock?

Celgene's stock was sold by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Atalanta Sosnoff Capital LLC, Bank of Montreal Can, Chesley Taft & Associates LLC, Westpac Banking Corp, Pennsylvania Trust Co, Factory Mutual Insurance Co. and Alta Capital Management LLC. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene.

Who bought Celgene stock? Who is buying Celgene stock?

Celgene's stock was acquired by a variety of institutional investors in the last quarter, including Penn Davis Mcfarland Inc., LGT Capital Partners LTD., WIM Asset Management HK Ltd, Schwab Charles Investment Management Inc., State of Alaska Department of Revenue, Bristol John W & Co. Inc. NY, DnB Asset Management AS and Capital Investment Services of America Inc.. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene.

How do I buy Celgene stock?

Shares of Celgene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of Celgene stock can currently be purchased for approximately $102.91.

How big of a company is Celgene?

Celgene has a market capitalization of $81.02 billion and generates $11.23 billion in revenue each year. The biopharmaceutical company earns $2.00 billion in net income (profit) each year or $4.24 on an earnings per share basis. Celgene employs 7,132 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 Morris Ave, SUMMIT, NJ 07901-3915, United States. The biopharmaceutical company can be reached via phone at +1-908-6739000 or via email at [email protected]


MarketBeat Community Rating for Celgene (CELG)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  1,687 (Vote Outperform)
Underperform Votes:  502 (Vote Underperform)
Total Votes:  2,189
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celgene (NASDAQ:CELG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.532.652.662.73
Ratings Breakdown: 1 Sell Rating(s)
12 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $130.14$135.63$149.03$141.27
Price Target Upside: 26.46% upside27.56% upside21.78% upside5.31% upside

Celgene (NASDAQ:CELG) Consensus Price Target History

Price Target History for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/23/2018BTIG ResearchReiterated RatingHoldLowView Rating Details
1/23/2018Cantor FitzgeraldSet Price TargetHold$112.00LowView Rating Details
1/18/2018Piper Jaffray CompaniesReiterated RatingHold$104.00LowView Rating Details
1/17/2018MizuhoReiterated RatingBuy$128.00HighView Rating Details
1/10/2018GuggenheimReiterated RatingBuy$147.00LowView Rating Details
1/8/2018SunTrust BanksSet Price TargetBuy$127.00MediumView Rating Details
1/8/2018Credit Suisse GroupSet Price TargetBuy$125.00MediumView Rating Details
1/8/2018Stifel NicolausSet Price TargetBuy$130.00MediumView Rating Details
1/8/2018Deutsche BankSet Price TargetHold$110.00LowView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$166.00HighView Rating Details
1/5/2018Bank of AmericaDowngradeBuy -> Neutral$104.68 -> $120.00MediumView Rating Details
1/4/2018Royal Bank of CanadaReiterated RatingBuy$147.00HighView Rating Details
12/27/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$121.00HighView Rating Details
12/22/2017Leerink SwannReiterated RatingBuy$120.00LowView Rating Details
12/22/2017BMO Capital MarketsReiterated RatingBuy$147.00LowView Rating Details
12/22/2017CitigroupReiterated RatingHoldMediumView Rating Details
12/8/2017Atlantic SecuritiesUpgradeNeutral -> OverweightHighView Rating Details
11/22/2017CannReiterated RatingBuy$166.00N/AView Rating Details
11/16/2017Canaccord GenuitySet Price TargetBuy$140.00N/AView Rating Details
10/27/2017JPMorgan Chase & Co.Set Price TargetBuy$123.00N/AView Rating Details
10/27/2017BarclaysReiterated RatingEqual Weight -> Equal Weight$135.00 -> $105.00N/AView Rating Details
10/27/2017Goldman Sachs GroupReiterated RatingSell$116.00 -> $91.00N/AView Rating Details
10/27/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
10/27/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
10/27/2017Robert W. BairdReiterated RatingHold$103.00N/AView Rating Details
10/26/2017Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
10/20/2017William BlairReiterated RatingOutperformN/AView Rating Details
10/16/2017Jefferies GroupReiterated RatingBuy$160.00N/AView Rating Details
9/12/2017CowenReiterated RatingBuy$150.00LowView Rating Details
7/31/2017ArgusUpgradeHold -> Buy$96.93 -> $160.00LowView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
4/28/2016Raymond James FinancialReiterated RatingBuyN/AView Rating Details
(Data available from 1/23/2016 forward)

Earnings

Celgene (NASDAQ:CELG) Earnings History and Estimates Chart

Earnings by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2018$1.94N/AView Earnings Details
10/26/2017Q3 2017$1.87$1.91$3.42 billion$3.29 billionViewN/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.23 billion$3.27 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
10/28/2010Q3 2010$0.32$0.32ViewN/AView Earnings Details
7/29/2010Q2 2010$0.30$0.30ViewN/AView Earnings Details
4/29/2010Q1 2010$0.28$0.27ViewN/AView Earnings Details
1/28/2010Q4 2009$0.29$0.29ViewN/AView Earnings Details
10/22/2009Q3 2009$0.25$0.25ViewN/AView Earnings Details
7/23/2009Q2 2009$0.21$0.20ViewN/AView Earnings Details
4/30/2009Q1 2009$0.20$0.16ViewN/AView Earnings Details
1/29/2009Q4 2008$0.19$0.19ViewN/AView Earnings Details
10/23/2008Q3 2008$0.18$0.17ViewN/AView Earnings Details
7/24/2008Q2 2008$0.16$0.15ViewN/AView Earnings Details
5/8/2008Q1 2008$0.16$0.17ViewN/AView Earnings Details
1/31/2008Q4 2007$0.15$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Celgene (NASDAQ:CELG) Earnings Estimates

2018 EPS Consensus Estimate: $8.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$1.89$1.89$1.89
Q2 20181$2.08$2.08$2.08
Q3 20181$2.13$2.13$2.13
Q4 20181$2.28$2.28$2.28
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene (NASDAQ:CELG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Celgene (NASDAQ CELG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 79.54%
Insider Trades by Quarter for Celgene (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/25/2017Terrie CurranInsiderSell1,727$143.89$248,498.033,925View SEC Filing  
9/12/2017Gilla KaplanDirectorSell9,250$141.56$1,309,430.0085,551View SEC Filing  
9/5/2017Michael D CaseyDirectorSell9,250$139.03$1,286,027.509,250View SEC Filing  
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.1269,424View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.0076,301View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.0032,877View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.005,000View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.801,033,909View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.509,250View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.304,004View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.0032,169View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.3973,109View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00778View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.0018,600View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.5650,000View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.0031,332View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.4072,142View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.0042,919View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.001,022,201View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.001,122,201View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.2872,518View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.0019,785View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.0082,449View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.6888,485View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.0088,485View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.1625,705View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00100,671View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.7850View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.0022,688View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.7815,349View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celgene (NASDAQ CELG) News Headlines

Source:
DateHeadline
Celgene to buy Juno for $9 billion to boost CAR-T expertiseCelgene to buy Juno for $9 billion to boost CAR-T expertise
www.businessinsider.com - January 23 at 8:41 AM
BRIEF-Juno Therapeutics Says If Deal Terminated By Co Or Celgene, Fee Of $300 Mln May Be Payable By Co To CelgeneBRIEF-Juno Therapeutics Says If Deal Terminated By Co Or Celgene, Fee Of $300 Mln May Be Payable By Co To Celgene
www.reuters.com - January 23 at 8:41 AM
How Junos CEO broke the $9 billion takeover news to employees, vendors and foundersHow Juno's CEO broke the $9 billion takeover news to employees, vendors and founders
finance.yahoo.com - January 23 at 8:41 AM
[$$] High Prices Won’t Deter Biotech Deals[$$] High Prices Won’t Deter Biotech Deals
finance.yahoo.com - January 23 at 8:41 AM
Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMIImmunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI
finance.yahoo.com - January 23 at 8:41 AM
These 3 Stocks Have Doubled Investors' MoneyThese 3 Stocks Have Doubled Investors' Money
finance.yahoo.com - January 23 at 8:41 AM
Celgene’s Acquisition of Juno Has Sent This Mostly Unknown Small Cap CAR-T Stock FlyingCelgene’s Acquisition of Juno Has Sent This Mostly Unknown Small Cap CAR-T Stock Flying
finance.yahoo.com - January 23 at 8:41 AM
Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?
finance.yahoo.com - January 23 at 8:41 AM
Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M&ATwo CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M&A
finance.yahoo.com - January 23 at 8:41 AM
Celgene (CELG) Stock Rating Reaffirmed by BTIG ResearchCelgene (CELG) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - January 23 at 8:22 AM
Celgenes Investments Are SoaringCelgene's Investments Are Soaring
www.fool.com - January 23 at 8:01 AM
The Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl - BenzingaThe Market In 5 Minutes: Celgene Buys Juno, Netflix Earnings Preview, Eagles And Patriots Advance To Super Bowl - Benzinga
www.benzinga.com - January 22 at 3:20 PM
Celgene Is Paying $9 Billion for Juno Therapeutics in Blockbuster Cancer Drug Deal - FortuneCelgene Is Paying $9 Billion for Juno Therapeutics in Blockbuster Cancer Drug Deal - Fortune
fortune.com - January 22 at 3:20 PM
Morning Movers: Juno Soars on Celgene Takeout; GE Slumps on Merrill Cut - BarronsMorning Movers: Juno Soars on Celgene Takeout; GE Slumps on Merrill Cut - Barron's
www.barrons.com - January 22 at 3:20 PM
Hackers Have Stolen $1.5 Million Per Month from Crypto Funds : LIVE MARKETS BLOGHackers Have Stolen $1.5 Million Per Month from Crypto Funds : LIVE MARKETS BLOG
finance.yahoo.com - January 22 at 3:20 PM
[$$] Big Drugmakers Pay Big Prices for Promising Biotechs[$$] Big Drugmakers Pay Big Prices for Promising Biotechs
finance.yahoo.com - January 22 at 3:20 PM
Energy and technology companies lead US stocks higherEnergy and technology companies lead US stocks higher
finance.yahoo.com - January 22 at 3:20 PM
Celgene & Juno: The Latest in a Bumper Crop of Biotech M&A?Celgene & Juno: The Latest in a Bumper Crop of Biotech M&A?
finance.yahoo.com - January 22 at 3:20 PM
Why Celgene Corporation Stock Is ALL About the BuyoutsWhy Celgene Corporation Stock Is ALL About the Buyouts
investorplace.com - January 22 at 11:34 AM
ZIOPHARM riding the Celgene/Juno wave, up 22%ZIOPHARM riding the Celgene/Juno wave, up 22%
seekingalpha.com - January 22 at 11:18 AM
Celgene to buy Juno Therapeutics for $9 billion - NasdaqCelgene to buy Juno Therapeutics for $9 billion - Nasdaq
www.nasdaq.com - January 22 at 7:46 AM
Shares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offerShares of biotech Juno, already up 50% on deal hopes, skyrocket on actual Celgene $9 billion offer
finance.yahoo.com - January 22 at 7:46 AM
Celgene buying Juno Therapeutics for $9 billionCelgene buying Juno Therapeutics for $9 billion
finance.yahoo.com - January 22 at 7:46 AM
Celgene to Buy Juno for $9 Billion, Signaling Cancer AspirationsCelgene to Buy Juno for $9 Billion, Signaling Cancer Aspirations
finance.yahoo.com - January 22 at 7:46 AM
Sanofi Will Buy Bioverativ; Celgene Will Acquire Juno TherapeuticsSanofi Will Buy Bioverativ; Celgene Will Acquire Juno Therapeutics
finance.yahoo.com - January 22 at 7:46 AM
[$$] Celgene to Buy Juno Therapeutics for $9 Billion[$$] Celgene to Buy Juno Therapeutics for $9 Billion
finance.yahoo.com - January 22 at 7:46 AM
Celgene Makes $9 Billion Cancer Treatment Play for Juno TherapeuticsCelgene Makes $9 Billion Cancer Treatment Play for Juno Therapeutics
finance.yahoo.com - January 22 at 7:46 AM
Celgene to acquire Juno Therapeutics for $9 billion, or $87 a shareCelgene to acquire Juno Therapeutics for $9 billion, or $87 a share
finance.yahoo.com - January 22 at 7:46 AM
Stocks making the biggest moves premarket: JUNO, CELG, AIG, HAL, BIVV, ADM, DNKN & moreStocks making the biggest moves premarket: JUNO, CELG, AIG, HAL, BIVV, ADM, DNKN & more
finance.yahoo.com - January 22 at 7:46 AM
Celgene takes out Juno for $9BCelgene takes out Juno for $9B
seekingalpha.com - January 22 at 7:20 AM
Leerink Swann Weighs in on Celgene Co.s FY2017 Earnings (CELG)Leerink Swann Weighs in on Celgene Co.'s FY2017 Earnings (CELG)
www.americanbankingnews.com - January 22 at 2:40 AM
BidaskClub Lowers Celgene (CELG) to SellBidaskClub Lowers Celgene (CELG) to Sell
www.americanbankingnews.com - January 20 at 11:12 AM
Investigational Data Presented at ASCO GI Evaluate ABRAXANE® Regimen for Patients with Locally Advanced Pancreatic CancerInvestigational Data Presented at ASCO GI Evaluate ABRAXANE® Regimen for Patients with Locally Advanced Pancreatic Cancer
finance.yahoo.com - January 20 at 9:55 AM
Healthcare: Is Celgene Going to Buy Juno Therapeutics? - Motley FoolHealthcare: Is Celgene Going to Buy Juno Therapeutics? - Motley Fool
www.fool.com - January 19 at 5:28 PM
Is Celgene (CELG) Looking to Take Over Juno Therapeutics? - Yahoo FinanceIs Celgene (CELG) Looking to Take Over Juno Therapeutics? - Yahoo Finance
finance.yahoo.com - January 19 at 5:28 PM
A Survey Of Celgenes M&A StrategyA Survey Of Celgene's M&A Strategy
feeds.benzinga.com - January 19 at 11:31 AM
Will This Tiny Biotech Be Celgenes Next Takeover Target?Will This Tiny Biotech Be Celgene's Next Takeover Target?
www.fool.com - January 19 at 11:03 AM
Juno Hits 52-Week High on Celgene's Rumored Buyout InterestJuno Hits 52-Week High on Celgene's Rumored Buyout Interest
finance.yahoo.com - January 19 at 11:03 AM
Will This Tiny Biotech Be Celgene's Next Takeover Target?Will This Tiny Biotech Be Celgene's Next Takeover Target?
finance.yahoo.com - January 19 at 11:03 AM
Celgene Could Be Bulking Up Very FastCelgene Could Be Bulking Up Very Fast
finance.yahoo.com - January 19 at 11:03 AM
Celgene Corporation Stock Needs More Than a Juno Acquisition to ThriveCelgene Corporation Stock Needs More Than a Juno Acquisition to Thrive
investorplace.com - January 19 at 7:10 AM
Celgene (CELG) Receives Hold Rating from Piper Jaffray CompaniesCelgene (CELG) Receives Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - January 18 at 9:16 PM
M&A Waves Pushing Biotech ETFs HigherM&A Waves Pushing Biotech ETFs Higher
finance.yahoo.com - January 18 at 4:33 PM
U.S. Investors Swarm Chinas Biotech LeaderU.S. Investors Swarm China's Biotech Leader
finance.yahoo.com - January 18 at 4:33 PM
Celgenes Otezla an Orphan Drug in U.S. for pediatric UCCelgene's Otezla an Orphan Drug in U.S. for pediatric UC
seekingalpha.com - January 18 at 3:59 PM
A major cancer drugmaker may need to buy its way out of a looming disasterA major cancer drugmaker may need to buy its way out of a looming disaster
www.cnbc.com - January 18 at 1:49 PM
Wall Street Reacts To Celgenes Reported Interest In JunoWall Street Reacts To Celgene's Reported Interest In Juno
finance.yahoo.com - January 18 at 10:46 AM
What's Juno Therapeutics Worth to Celgene?What's Juno Therapeutics Worth to Celgene?
finance.yahoo.com - January 18 at 10:46 AM
$3.50 Billion in Sales Expected for Celgene Co. (CELG) This Quarter$3.50 Billion in Sales Expected for Celgene Co. (CELG) This Quarter
www.americanbankingnews.com - January 18 at 8:42 AM
Celgene (CELG) Scheduled to Post Quarterly Earnings on ThursdayCelgene (CELG) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - January 18 at 1:26 AM

SEC Filings

Celgene (NASDAQ:CELG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celgene (NASDAQ:CELG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celgene (NASDAQ CELG) Stock Chart for Tuesday, January, 23, 2018

Loading chart…

This page was last updated on 1/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.